D-MARDs

What Are D-MARDs?

Disease-Modifying Anti-Rheumatic Drugs (D-MARDs) are widely prescribed for autoimmune forms of arthritis such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (A.S.). Unlike painkillers, which only mask symptoms, D-MARDs are designed to slow down the underlying disease process by altering immune system function.

They can reduce joint inflammation, slow damage, and improve mobility. For this reason, rheumatologists often prescribe them early, particularly methotrexate, which is considered the “anchor drug.”

But while D-MARDs can provide meaningful short-term benefit, they also carry a long list of side effects and risks. They don’t address the root causes of inflammation – diet, lifestyle, and environment – which are often the very factors that drive autoimmune disease. Many people find that when they commit to comprehensive lifestyle changes, their inflammation reduces so much that they can lower or even stop their medications under medical supervision.

Methotrexate: The Anchor D-MARD

Methotrexate is the most prescribed D-MARD globally, often the first medication given after diagnosis.

• How it works: Methotrexate affects folate-dependent processes in immune cells, reducing the excessive immune activity that drives inflammation.

• Effectiveness: Around 60–70% of patients notice improvements in pain and swelling within 6–8 weeks.

• Side effects: Common ones include nausea, fatigue, mouth sores, and lowered blood counts. More serious risks include liver fibrosis, lung inflammation (1–3% of users), and increased susceptibility to infections. Even at low doses, methotrexate puts ongoing strain on the liver and immune system, requiring regular blood monitoring every 4–8 weeks.

• Reality check: While methotrexate is considered effective, many patients discontinue it within 1–2 years due to side effects or poor tolerance.

Other Conventional D-MARDs

Besides methotrexate, other drugs in this category include:

• Sulfasalazine – Often combined with methotrexate. Side effects may include rashes, digestive upset, headaches, and lowered blood counts.

• Hydroxychloroquine – One of the “milder” DMARDs, sometimes preferred for lupus and mild RA. Long-term use can damage the retina (about 1% after 5 years, higher after 10 years).

• Leflunomide – Comparable to methotrexate in strength, but with a higher risk of liver toxicity, diarrhoea, hair loss, and immune suppression. Its extremely long half-life means side effects may continue even after stopping.

Key point: while these drugs may slow joint damage, they are not without consequence. Most require lifelong monitoring, and nearly all carry risks that increase with time.

Biologic and Targeted Synthetic D-MARDs

For people who do not respond well to conventional D-MARDs, newer biologic D-MARDs and targeted synthetic D-MARDs (ts D-MARDs) are often prescribed. These medications can be very effective at suppressing inflammation, but they also come with serious risks, particularly when used long-term.

Biologics

Biologics are engineered antibodies or proteins that target specific immune pathways. The most common are TNF inhibitors (adalimumab/Humira, etanercept/Enbrel, infliximab/Remicade, golimumab/Simponi, certolizumab/Cimzia). Others include IL-6 blockers (tocilizumab), IL-17 blockers (secukinumab), and B-cell therapy (rituximab).

They are often effective in patients who fail methotrexate, but this immune suppression comes at a cost:

• Infections: Risk of tuberculosis and shingles reactivation is well documented. Pneumonia and opportunistic infections are also more likely.

• Cancer: Some studies suggest increased risk of lymphoma and skin cancers with prolonged use.

• Neurological complications: Rare cases of multiple sclerosis-like demyelination have been reported.

• Cardiovascular risks: Warnings include increased risk of heart failure, strokes, and in the case of etanercept (Enbrel) and similar drugs, rare reports of sudden cardiac death.

• Autoimmune reactions: These medications can paradoxically trigger lupus-like syndromes or other autoimmune conditions.

• General side effects: Injection site reactions, fatigue, headaches, and allergic responses are common.

👉 Because TNF inhibitors remain the most commonly prescribed biologics worldwide, we’ve created a dedicated page on TNF inhibitors where you can learn more about how they work, their benefits, and their full range of side effects.

Targeted Synthetic D-MARDs (ts D-MARDs)

These newer oral medications, such as JAK inhibitors (tofacitinib, baricitinib, upadacitinib), block specific immune signalling pathways inside cells. They work quickly and are convenient as tablets rather than injections. However, recent safety reviews by the FDA and EMA have highlighted increased risks of:

• Serious infections

• Blood clots (deep vein thrombosis, pulmonary embolism)

• Cardiovascular events (heart attacks and strokes)

• Increased mortality with long-term use

Globally, biologics and JAK inhibitors are changing how arthritis is managed, but it is important to remember that they are not curative. They may reduce disease activity, but they do not address the root drivers of inflammation. They are also expensive, immunosuppressive, and associated with serious long-term risks – which is why many people seek more sustainable healing through lifestyle changes. 

Natural and Lifestyle Alternatives

Unlike medications, lifestyle changes aim to address the root drivers of inflammation. Many people with arthritis have found that with sustained changes to diet, exercise, gut health, stress management, and sleep, their symptoms decrease to the point where D-MARDs are no longer necessary.

Research shows that:

• An anti-inflammatory, whole food, plant-based diet – where specific triggers have been removed – can reduce systemic inflammation, lower CRP and ESR (inflammatory markers), and improve quality of life.

• Weight reduction of just 5–10% of body weight in overweight patients can dramatically reduce joint stress and inflammatory load.

• Stress reduction and meditation have been shown to lower inflammatory cytokines and improve pain perception.

Alongside lifestyle changes, certain natural compounds show D-MARD-like, though milder, effects:

• Curcumin (turmeric extract) – Reduces RA disease activity scores, with up to 50% improvement in some trials.

• Omega-3 fatty acids – Meta-analyses show reductions in morning stiffness and tender joint counts; some patients reduce NSAID use by 20–30%.

• Boswellia serrata – Improves pain and mobility in osteoarthritis and RA studies.

• Polyphenols like Quercetin, Resveratrol and Sulforaphane are plant compounds showing COX/LOX and inflammatory cytokine inhibition in both animal and early human studies.

• Green tea catechins (EGCG) – Preliminary research shows reductions in autoimmune inflammation.

While not as immediately powerful as pharmaceuticals, these natural strategies are low-risk and support overall health, making them a compelling first-line or adjunctive choice for many seeking a natural path.

Safety, Monitoring, and Patient Choices

• All D-MARDs suppress immunity, increasing infection risk.

• Liver and blood monitoring is mandatory to detect silent damage before it becomes severe.

• Stopping suddenly can cause disease flares – always taper under medical supervision.

• Many patients ultimately face a decision: stay on powerful medications with growing side effects, or make lifestyle changes that address the cause.

References

• Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020;79:685–699.

• Singh JA, et al. 2016 American College of Rheumatology guidelines for RA treatment. Arthritis Care Res. 2016;68:1–25.

• Kremer JM. Methotrexate in the treatment of rheumatoid arthritis: update 2019. J Rheumatol. 2019.

• van Vollenhoven R. Biologics in rheumatoid arthritis: clinical use and safety. Lancet. 2019.

• Taylor PC, et al. JAK inhibitors in RA – clinical utility and safety concerns. Nat Rev Rheumatol. 2017.

• Ytterberg SR, et al. Cardiovascular and cancer risk with tofacitinib compared with TNF inhibitors. NEJM. 2022;386:316–326.

• Dixon WG, et al. Serious infection risk with TNF inhibitors in RA. Arthritis Rheum. 2010;62(10):2855–2865.

• Abdelghaffar H, et al. Curcumin and rheumatoid arthritis: systematic review and meta-analysis. Phytother Res. 2021.

• Goldberg RJ, Katz J. A meta-analysis of fish oil in rheumatoid arthritis. Semin Arthritis Rheum. 2007.

• Kimmatkar N, et al. Efficacy of Boswellia serrata extract in osteoarthritis of the knee. Phytomedicine. 2003.

• Matcham F, et al. Impact of methotrexate on patient-reported outcomes in RA. Rheumatology. 2016.

• Pincus T, et al. Long-term outcomes in RA: importance of early DMARD use. Arthritis Rheum. 2003.

• Ortega Castro R, et al. Lifestyle interventions and inflammation in autoimmune arthritis. Clin Rheumatol. 2020.

⚠️ Disclaimer: This information is for educational purposes only and is not medical advice. Always consult a qualified healthcare professional before making changes to your medication or treatment plan. See full disclaimer here.